Price Floor or Growth Ceiling: How a Cardiovascular Device Company Used Market Research and Consulting to Decide Whether Drug-Eluting Stents Were Worth Entering in Southeast Asia

Drug-eluting stents in emerging markets present an entry decision shaped by a specific structural tension. The overall market looks attractive because cardiovascular disease incidence is rising and stent procedure volumes are growing.

The client’s business development team had gathered pricing intelligence from distributor conversations that suggested wide variation across markets and channels, without a clear picture of whether the private hospital segment was large enough and consistently priced enough to constitute a viable primary entry target, or whether the route to commercial viability required eventually winning public tender volume at margin levels the client’s cost structure could not sustain.

Filing regulatory submissions across three countries without resolving that question would commit a significant registration budget to markets that might only be commercially viable through a channel the client could not reach profitably without investment it had not yet planned for.

Key Challenges

• No independent market research establishing drug-eluting stent pricing levels, tender structures, and public-private volume distribution across the three target markets.
• Conflicting distributor-sourced pricing intelligence that had not been validated against actual tender award data or private hospital procurement records.
• No structured assessment of whether the private hospital segment in any target market was large enough at the right price to support a registration investment without public tender volume.
• Risk of committing a three-country regulatory filing budget to markets where the only commercially viable entry channel required cost economics the client did not have.
• No entry sequence analysis ranking the three markets by expected time-to-revenue at the client’s margin requirements.
• Commercial director pressure to produce a market entry recommendation before the next regulatory affairs budget cycle committed the filing fees.

Drug-eluting stent market entry in Southeast Asia is not a single decision. It is a segmentation decision about which channel, public tender or private hospital, is commercially viable for a specific manufacturer’s cost structure, and a sequencing decision about which country offers the fastest route to that channel at adequate volume. Getting both wrong is expensive. Getting both right requires data that distributor conversations alone cannot reliably provide.